Back HIV/AIDS HIV/AIDS Topics HIV Disease Progression

IAS 2013: HIV, Inflammation, and Aging [VIDEO]

HIV has become a chronic disease for people who have access and respond to antiretroviral therapy, but it leads to persistent immune activation and inflammation that could cause problems as people with HIV reach their 60s, 70s, and 80s, Steven Deeks from the University of California at San Francisco said in a keynote address at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

alt

Read more:

International AIDS Society Conference Starts Sunday

The 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) will kick of Sunday, June 30, in Kuala Lumpur Malaysia. Key areas of interest will include new developments in antiretroviral therapy, biomedical HIV prevention, and improving access to and retention in care.alt

Read more:

Younger People with HIV Are Missing Out in the Continuum of Care

Young people with HIV are less likely to access and benefit from HIV care and treatment at all levels of the "care cascade" from testing to starting antiretroviral therapy (ART) to achieving viral suppression, according to findings reported in the June 17, 2013, advance edition of JAMA Internal Medicine. Overall, only about 25% of HIV positive people achieved undetectable viral load.

alt

Read more:

People with Well-Controlled HIV Can Match Lifespan of HIV Negatives

People with HIV who are able to achieve good viral suppression and CD4 cell recovery on antiretroviral therapy (ART) have a mortality rate similar to that of uninfected people in the general population, according to results from the large SMART and ESPRIT studies, published in the March 27, 2013 issue of AIDS.alt

Read more:

Even Small Viral Load Reduction Is Beneficial for People with Highly Resistant HIV

Antiretroviral therapy (ART) can help raise CD4 T-cell counts even if it does not produce undetectable HIV RNA due to extensive drug resistance, indicating that treatment likely has immunological benefits even for people with few therapeutic options, according to a report in the March 1, 2013 Journal of Infectious Diseases.

alt

Read more: